Alternative splicing modulation restores disease-selective RNA processing
PrimaryBiosplice's core causal theory is that small molecules targeting CLK/DYRK family kinases can change disease-selective RNA splice-site selection, thereby shifting pathogenic gene-expression programs toward healthier states. Because alternative splicing regulates which protein isoforms are produced, modulating splicing is proposed to affect multiple age-related or healthspan-limiting diseases rather than only blocking a single downstream symptom. A testable prediction is that CLK/DYRK-targeting compounds should produce measurable changes in disease-relevant splice isoforms and downstream pathway activity, and that these molecular changes should translate into functional benefit in diseases where aberrant splicing contributes to pathology, including osteoarthritis, oncology, neurology, and metabolic disease programs.
Popperian evaluation
The starting biology is credible. CLK and DYRK kinases can alter splice-site choice, alternative splicing changes protein isoforms, and DYRK1A biology has disease links in osteoarthritis, leukemia models, tauopathy, and cell-cycle control. The weak point is selectivity: the theory needs disease-relevant splicing to move without broad disruption of normal RNA processing. That is plausible, but still a live risk.
Supporting evidence: Multiple cited studies support CLK/DYRK-targeting small molecules changing RNA splicing or downstream pathway activity.; Alternative splicing is a direct mechanism for changing protein isoform production and pathway behavior.; Lorecivivint is described as a CLK/DYRK1A inhibitor and Wnt pathway modulator, with osteoarthritis clinical data and pathway effects.
Counter evidence: The evidence context treats disease-selective splicing as an assumption, not a settled fact.; Functional effects in neurology and cancer include DYRK1A pathway biology, but they do not all prove that splice modulation itself is the causal driver.
The theory explains a real chain: kinase inhibition changes RNA processing or pathway activity, and some disease models show functional benefit. It fits the osteoarthritis pathway data and the leukemia splicing result reasonably well. But it does not yet beat simpler alternatives across the portfolio. Lorecivivint benefits could come through Wnt and inflammatory pathway modulation without splice correction being the key event, and DYRK1A effects in tauopathy may reflect kinase signaling rather than disease-selective RNA processing.
Supporting evidence: Lorecivivint studies report modulation of inflammatory and Wnt-related pathways, consistent with downstream effects of CLK/DYRK inhibition.; RNA splicing modulation enhanced response to BCL2 inhibition in leukemia, directly supporting an oncology use case for splicing-directed intervention.; DYRK1A inhibition reduced tau pathology, neuroinflammation, and behavioral deficits in a repetitive head injury tauopathy model.
Counter evidence: The osteoarthritis evidence supports CLK/DYRK and Wnt biology more directly than it supports RNA splice-site correction as the main cause of clinical benefit.; The theory spans osteoarthritis, oncology, neurology, and metabolic disease, but the evidence is uneven across those areas.; Correlation between aberrant splicing or CLK/DYRK pathway activity and disease pathology does not prove causation.
This is testable in a clean way. A compound should change prespecified disease-relevant splice isoforms, shift downstream pathway markers, and produce functional benefit in indications where the target biology matters. The theory would take a real hit if clinical benefit appeared without the predicted RNA or pathway changes, or if splice changes occurred broadly in healthy tissue with no disease-selective signal.
Supporting evidence: The theory predicts measurable changes in disease-relevant splice isoforms after CLK/DYRK-targeting treatment.; It predicts downstream pathway changes, including inflammatory and Wnt-related activity in osteoarthritis.; It predicts functional benefit in diseases where aberrant splicing or CLK/DYRK-linked pathways contribute to pathology.
Counter evidence: The broad multi-disease framing makes failure in one indication less decisive unless the theory defines indication-specific biomarker gates in advance.; Some observed benefits could be attributed to non-splicing kinase effects unless experiments separate splice modulation from other CLK/DYRK signaling.
Reasoning tree
Public endorsements
The evidence identifies Biosplice management and describes company programs and publications, but it does not show any public statement from the named person about CLK/DYRK targeting, alternative splicing modulation, or the theory's causal claim. The person record itself also looks noisy, because "Directors Management Advisors Contact" is navigation text rather than a clear individual name. On this record, there is no public endorsement, mention, or contradiction to attribute.
Evidence publication IDs: b68c7cb1-810a-4b72-bed2-44a6f8ed54a7, 03f404a5-c597-4c44-862a-2c63677dc247, fee44356-8ee7-47c1-802e-f398dd2e8369
The public statements provided from Erich Horsley cover lorecivivint's clinical progress, the NDA submission, the company rebrand, and osteoarthritis patient need. None of them mention alternative splicing, CLK or DYRK kinases, RNA processing, splice-site selection, or the claim that modulating splicing can shift disease programs toward healthier states. On this record, he stays silent on the theory itself.
The dossier does not show this person making any public statement about Biosplice's splicing theory. The quotes are about other companies and other executive chairmen, and the Biosplice management page only shows company personnel, not a theory-specific endorsement or contradiction. On this record, the person stays silent.
There is no public evidence here. No quotes, records, or publications tie Finian Tan to this splicing-modulation theory, so the defensible call is silence rather than endorsement, mention, or contradiction.
The evidence only shows John A. Bergfeld listed on Biosplice's advisor page as a clinical advisor. There is no public quote, publication, or attributed statement from him about Biosplice's theory that CLK/DYRK-targeting small molecules can modulate alternative splicing to improve disease outcomes. Advisory affiliation alone is too thin to count as a public endorsement of that specific causal claim.